Enlivex Ltd. (ENLV)
NASDAQ: ENLV · Real-Time Price · USD
1.390
-0.070 (-4.79%)
At close: Nov 4, 2026, 4:00 PM EST
1.410
+0.020 (1.44%)
After-hours: Nov 4, 2026, 7:30 PM EST
Enlivex Employees
Enlivex had 34 employees as of December 31, 2025. The number of employees decreased by 37 or 52.11% compared to the previous year. That makes Enlivex the 36,589th largest employer in the world and 5,072nd in the United States.
Employees
34
Change
-37
Growth
-52.11%
Revenue / Employee
n/a
Profits / Employee
$93,820,441
Market Cap
1.73M
Employees Chart
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 34 | -37 | -52.11% |
| Dec 31, 2021 | 71 | 21 | 42.00% |
| Dec 31, 2020 | 50 | 14 | 38.89% |
| Dec 31, 2019 | 36 | 5 | 16.13% |
| Dec 31, 2018 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PMGC Holdings | 34 |
| GeoVax Labs | 19 |
| BioRestorative Therapies | 14 |
| Genprex | 13 |
| Revelation Biosciences | 9 |
| Kairos Pharma | 4 |
| XORTX Therapeutics | 3 |
| Oragenics | 3 |
ENLV News
- 2 days ago - Enlivex reports favorable 12-month Allocetra knee osteoarthritis trial data - TheFly
- 2 days ago - Enlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response - GlobeNewsWire
- 7 days ago - Enlivex Therapeutics randomizes patients in Allocetra trial - TheFly
- 7 days ago - Enlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis - GlobeNewsWire
- 8 days ago - Enlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal - GlobeNewsWire
- 9 days ago - Enlivex Therapeutics trading halted, news pending - TheFly
- 13 days ago - Enlivex Therapeutics implements 1-for-16 reverse share split - TheFly
- 13 days ago - Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026 - GlobeNewsWire